July 2025
1. THE LANCET
   Transformative advances in Crohn's disease management.
   Lancet. 2025;406:307.
   

   >> Share

   
   
2. PANACCIONE R, Feagan BG, Afzali A, Rubin DT, et al
   Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double
   Lancet. 2025 Jul 17:S0140-6736(25)00681-6. doi: 10.1016/S0140-6736(25)00681.
   

   >> Share

   
   
3. DZIEGIELEWSKI C, Singh S
   Guselkumab for Crohn's disease: the IL-23 blockade revolution.
   Lancet. 2025 Jul 17:S0140-6736(25)00874-8. doi: 10.1016/S0140-6736(25)00874.
   

   >> Share

   
   December 2024
4. RUBIN DT, Allegretti JR, Panes J, Shipitofsky N, et al
   Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
   Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927.
   

   >> Share

   
   
5. GROS B, Targownik LE
   Guselkumab in the IL-23 inhibition landscape for ulcerative colitis.
   Lancet. 2024 Dec 17:S0140-6736(24)02262-1. doi: 10.1016/S0140-6736(24)02262.
   

   >> Share

   
   November 2024
6. FERRANTE M, D'Haens G, Jairath V, Danese S, et al
   Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
   Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
   

   >> Share

   
   
7. CHAPMAN TP, Satsangi J
   Expanding therapeutic options in Crohn's disease.
   Lancet. 2024 Nov 21:S0140-6736(24)01937-8. doi: 10.1016/S0140-6736(24)01937.
   

   >> Share

   
   October 2024
8. JAIRATH V, Acosta Felquer ML, Jaihyun Cho R
   IL-23 inhibition for chronic inflammatory disease.
   Lancet. 2024;404:1679-1692.
   

   >> Share

   
   
9. VIOLI F, Pignatelli P
   Thrombosis and inflammatory bowel disease.
   Lancet. 2024;404:1641.
   

   >> Share

   
   
10. KUMAR S, Goldsmith D
    Recognising renal and urological complications of Crohn's disease.
    Lancet. 2024;404:1640-1641.
    

    >> Share

    
    May 2024
11. LAMB CA, Titterton C, Banerjee R, Gomberg A, et al
    Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care.
    Lancet. 2024 May 17:S0140-6736(24)00983-8. doi: 10.1016/S0140-6736(24)00983.
    

    >> Share

    
    
12. LIBOW J
    The poetics of Crohn's disease.
    Lancet. 2024;403:1843.
    

    >> Share

    
    March 2024
13. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
    Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
    Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
    

    >> Share

    
    
14. DOLINGER M, Torres J, Vermeire S
    Crohn's disease.
    Lancet. 2024 Mar 1:S0140-6736(23)02586-2. doi: 10.1016/S0140-6736(23)02586.
    

    >> Share

    
    August 2023
15. LE BERRE C, Honap S, Peyrin-Biroulet L
    Ulcerative colitis.
    Lancet. 2023;402:571-584.
    

    >> Share

    
    March 2023
16. SANDBORN WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, et al
    Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Lancet. 2023 Mar 2:S0140-6736(23)00061-2. doi: 10.1016/S0140-6736(23)00061.
    

    >> Share

    
    
17. ATREYA R, Neurath MF
    The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis.
    Lancet. 2023 Mar 2:S0140-6736(23)00228-3. doi: 10.1016/S0140-6736(23)00228.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share